History & Overview Annual Report President's Pages Center News Community Affairs
Make a Gift Cycle for Survival Fred's Team Rock & Run on the River Yankees Universe Fund Thomas Blake Sr. Memorial Research Fund Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck Cookbook
Press Releases In the News Information for Journalists News@MSKCC
Manhattan New Jersey Long Island Westchester
Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days Job Search & Apply Online
Making an Appointment

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation from HLA-Compatible Unrelated Donors in Severe Aplastic Anemia

[Protocol 06-056]

Full Title :
FLUDARABINE-BASED CONDITIONING FOR ALLOGENEIC MARROW TRANSPLANTATION FROM HLA-COMPATIBLE UNRELATED DONORS IN SEVERE APLASTIC ANEMIA (BMT CTN PROTOCOL 0301)
Purpose :

Severe aplastic anemia is a blood disorder in which the bone marrow stops working, and produces few or no blood cells (such as white and red blood cells and platelets). Left untreated, aplastic anemia can cause death from infection or bleeding. A bone marrow transplant may therefore be performed to replace the patient's abnormal bone marrow with functioning marrow.

The bone marrow may come from a related donor or an unrelated donor whose marrow matches that of the recipient. In this study, investigators are evaluating a new approach to bone marrow transplantation for aplastic anemia in which the marrow is coming from an unrelated donor.

Before the transplant, the patient's immune function and abnormal bone marrow are suppressed using a combination of medications (usually anti-thymocyte globulin and cyclophosphamide) and total body irradiation. However, this "conditioning" regimen can cause side effects, especially due to the cyclophosphamide. In this study, researchers are adding a new drug called fludarabine to this conditioning regimen in hopes of reducing the dose of cyclophosphamide. They will determine what dose of cyclophosphamide should be used in the conditioning step when fludarabine is also used.

Eligibility :

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of severe aplastic anemia and have an unrelated matched bone marrow donor.
  • Patients may not have had prior stem cell or bone marrow transplantation.
  • Patients must be age 65 or younger.

For more information and to see if you are eligible for this study, please contact Dr. Hugo Castro-Malaspina at 212-639-8197.

Back to All Clinical Trials
Bookmark and SharePrintEmail This Page